For patients who experience graft-versus-host disease after transplant and do not respond to corticosteroids, ibrutunib leads to a high, durable response rate, according to results from a phase II trial. Dr. Miklos discusses these results.
Skip Nav Destination
David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease
December 30, 2021
Content License:Private